Such robust metabolic improvements not only help patients achieve weight loss but also significantly reduce their biological vulnerability to chronic diseases
[176] An analysis of events in the US FDA Adverse Event Reporting System suggests an association between several GLP-1 agonists (including semaglutide) and cutaneous reactions, such as dermal hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid, and morbilliform drug eruptions
Your bodys own GLP-1 production doesnt compensate when medication stops
Some patients will lose hair because of decreased caloric intake, specifically 900 calories or less
The Phase 3 SYNERGY trial (NCT06859268) will evaluate whether retatrutide can resolve steatohepatitis (liver inflammation) and fibrosis, endpoints that would be required for regulatory approval specifically for liver disease treatment
However, if they persist or worsen, its crucial to consult with a healthcare professional